OST-EFFECTIVENESS ANALYSIS OF ADJUVANT THERAPY WITH IMATINIB MESYLATE IN PATIENTS AFTER RESECTION OF LOCALIZED PRIMARY GASTROINTESTINAL STROMAL TUMOR
The purpose of this study was to estimate the costs and effectiveness of adjuvant imatinib therapy versus no treatment in patients who have undergone GIST resection. The analysis showed that adjuvant imatinib therapy is more costly compared with no treatment. However, it is more effective and can increase the life expectancy of patients.
imatinib, cost-effectiveness analysis